A bold truth first: obesity after menopause may fuel breast cancer progression through a hormone many overlook. And this is where the story gets especially important. New findings illuminate how estrone, not estradiol, rises as a key player in postmenopausal breast cancer risk among people with obesity, potentially driving inflammation and tumor growth. Here’s a clear, beginner-friendly rewrite of the core points, with added context to help understanding and a few prompts to spark thoughtful discussion.
Joyce Slingerland, MD, PhD, a professor at the Lombardi Comprehensive Cancer Center, highlights emerging evidence that links higher estrone levels to increased breast cancer risk and progression in postmenopausal women who are overweight or obese. In recent commentary with Contemporary OB/GYN, she explains how obesity-related changes in estrone may fuel inflammatory pathways and cancer biology after menopause.
Key background information helps make sense of the connection. After menopause, estradiol—the dominant and highly potent estrogen before menopause—drops substantially because ovarian estrogen production ends. Estradiol is known for anti-inflammatory effects in many experimental setups. In contrast, estrone becomes the main circulating estrogen in postmenopausal women. Estrone is produced mainly outside the ovaries, through the peripheral conversion of adrenal androgens (like androstenedione) in fat tissue. When someone has more fat tissue, estrone levels can rise nearly twofold, creating a hormonal environment that tends to promote inflammation.
Slingerland’s laboratory has directly compared estrone with estradiol in breast cancer models. They found that, even though estrone binds less strongly to estrogen receptors, it actually spurred faster breast cancer growth in mice. Estrone also activates NF-κB, a major signaling pathway that drives inflammation. Unlike estradiol, which can help dampen inflammation in some contexts, estrone appears to cooperate with NF-κB to drive inflammatory processes, expand breast cancer stem cell populations, and promote metastasis in both cell culture and animal studies.
Taken together, these findings suggest that higher estrone levels associated with obesity may be particularly harmful after menopause. This points to postmenopausal obesity as a meaningful risk factor for estrogen receptor–positive breast cancer and may also influence inflammatory processes relevant to ER-negative disease.
In exploring potential interventions, Slingerland discussed GLP-1 receptor agonists as a promising possibility. These medications could support weight loss and, by extension, lower estrone-driven inflammation, especially for breast cancer survivors who have completed primary cancer treatments such as surgery, radiation, and chemotherapy and may be on endocrine therapy. Since adipose tissue actively produces estrone, reducing fat mass could lessen inflammatory signals that contribute to tumor progression across breast cancer subtypes.
Clinically, the takeaway is straightforward: sustained weight management and regular exercise should be strongly encouraged for breast cancer patients and their families.
Future research directions focus on testing GLP-1 receptor agonists—alone or in combination with exercise—to see if they can reduce inflammatory signaling, bolster anti-tumor immune responses, and improve survivorship outcomes.
Bottom line for patients: maintaining a healthy weight and staying physically active may help lower the risk of recurrence and support better long-term outcomes.
No conflicts of interest were disclosed.
Reference
An overlooked hormone eyed as deadly driver of postmenopausal breast cancer in women with obesity. Georgetown University Medical Center. December 2, 2025. Accessed December 8, 2025. https://www.eurekalert.org/news-releases/1107155
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
